BioAdaptives, Inc. reported minimal revenue of $18,278 for the fiscal year ending December 31, 2025, a slight increase from $12,669 in the previous year. The company incurred a net loss of $1,557,898, compared to a loss of $899,161 in 2024. The increase in losses is attributed to higher operating expenses, which rose to $1,054,688 from $606,120 in the prior year. The company’s operating expenses included significant costs related to general and administrative expenses and professional fees, which accounted for $820,508 and $230,162, respectively.
In terms of strategic developments, BioAdaptives has been actively reformulating its product line and plans to launch new products in the second quarter of 2025. The company has also expanded its product offerings to include a canine health product, PawPa®Regen, and is finalizing the pre-launch phase of its cognitive enhancement product, MyndMed™. Additionally, BioAdaptives acquired the rights to the Lung Flute™, an FDA-cleared medical device, and is exploring partnerships with other medical device manufacturers to broaden its market reach.
Operationally, BioAdaptives has seen a modest increase in its inventory, which rose to $44,706 from $19,115 in 2024. The company’s total assets decreased to $225,901 from $261,885, while total liabilities increased significantly to $2,355,957 from $1,725,803, primarily due to a rise in derivative liabilities associated with convertible notes. The company’s employee count remains low, with only one full-time executive, relying on consultants and hourly labor for operational needs.
Looking ahead, BioAdaptives acknowledges the need for additional financing to support its operations and product development. The company plans to issue more shares of common stock to raise capital, although it faces uncertainties regarding its ability to secure sufficient funding. Management has expressed optimism about the potential for future growth and profitability, contingent on the successful implementation of its business plan and market conditions. However, there remains substantial doubt about the company's ability to continue as a going concern without adequate capital.
About BIOADAPTIVES, INC.
BioAdaptives, Inc. develops, markets, and distributes natural plant, fungi, and algal-based nutraceutical products and medical devices aimed at improving health and wellness for humans and animals. Its product portfolio focuses on weight management, anti-aging, antiviral functions, and cognitive enhancement. The company employs proprietary formulations and clinical research, targeting health-conscious consumers through direct-to-consumer digital marketing, telehealth partnerships, and affiliate programs, while outsourcing manufacturing to maintain operational flexibility.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.